FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

Data Compilation
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

Sumatriptan

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

56 API Suppliers, 26 USDMF, 15 CEP/COS, 4 JDMF, 14 EU WC, 7 KDMF, 18 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

28 Drugs in Development

28 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

451 FDF Dossiers, 105 FDA Orange Book, 266 Europe, 33 Canada, 13 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma, 1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

3 Parenteral, 1 Topical

DIGITAL CONTENT

36 News #PharmaBuzz

36 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions, 63 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

46 US Patents, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 6 Others

$ Xls

Filters

TABLET;ORAL - 60MG;EQ 10MG BASE

TABLET;ORAL - 500MG;EQ 85MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

POWDER;NASAL - EQ 11MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Sumatriptan

Sumatriptan

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

56 API Suppliers

26 USDMF

15 CEP/COS

4 JDMF

14 EU WC

7 KDMF

18 NDC API

24 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

28 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

451 FDF Dossiers

105 FDA Orange Book

266 Europe

33 Canada

13 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

3 Parenteral

1 Topical

DIGITAL CONTENT

36 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions

63 Regulatory FDF Prices

8 Annual Reports

MARKET PLACE

13 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

46 US Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

6 Others

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons